C4 Therapeutics (CCCC) Common Equity (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Common Equity of $234.2 million for Q1 2026, up 20.04% year-over-year from $195.1 million in Q1 2025, and down 8.71% quarter-over-quarter from $256.6 million in Q4 2025.
C4 Therapeutics (CCCC) Common Equity (2019 - 2026) Analysis & Trends
C4 Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $234.2 million for Q1 2026.
- In Q1 2026, Common Equity rose 20.04% year-over-year to $234.2 million; the TTM figure through Mar 2026 stood at $234.2 million (up 20.04% YoY), while the FY2025 annual figure was $256.6 million, up 18.8% from the prior year.
- Common Equity for Q1 2026 stood at $234.2 million, down from $256.6 million in the prior quarter.
- The five-year high for Common Equity was $364.5 million in Q1 2022, with the low at $154.4 million in Q3 2025.
- The 5-year median for Common Equity is $246.1 million (2023), against an average of $250.2 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity soared 38.23% in 2022, then tumbled 36.37% in 2025.
- C4 Therapeutics' Common Equity stood at $289.2 million in 2022, then slipped by 14.91% to $246.1 million in 2023, then slipped by 12.24% to $216.0 million in 2024, then advanced by 18.8% to $256.6 million in 2025, then slipped by 8.71% to $234.2 million in 2026.
- Business Quant data shows CCCC's Common Equity at $234.2 million in Q1 2026, $256.6 million in Q4 2025, and $154.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 247.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 247.27 Mn |
| Mar 31, 2026 | 234.25 Mn |
| Dec 31, 2025 | 256.59 Mn |
| Sep 30, 2025 | 154.41 Mn |
| Jun 30, 2025 | 174.06 Mn |
| Mar 31, 2025 | 195.14 Mn |
| Dec 31, 2024 | 215.99 Mn |
| Sep 30, 2024 | 242.66 Mn |
| Jun 30, 2024 | 247.06 Mn |
| Mar 31, 2024 | 258.28 Mn |
| Dec 31, 2023 | 246.11 Mn |
| Sep 30, 2023 | 216.02 Mn |
| Jun 30, 2023 | 233.71 Mn |
| Mar 31, 2023 | 262.47 Mn |
| Dec 31, 2022 | 289.23 Mn |
| Sep 30, 2022 | 318.18 Mn |
| Jun 30, 2022 | 344.59 Mn |
| Mar 31, 2022 | 364.53 Mn |
| Dec 31, 2021 | 389.61 Mn |
| Sep 30, 2021 | 398.78 Mn |